Logan Coy Related postsA First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid TumorsSeptember 11, 2026A Phase 3, randomised, double-blind, placebo-controlled, multicentre trial comparing trilaciclib versus placebo in limited-stage small cell lung cancerSeptember 11, 2026A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET AlterationsSeptember 11, 2026 Previous postA Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to RuxolitinibNext postA Phase 1a/1b, Open-label, Dose-escalation and Dose-expansion Study of UBX-303061 in Relapsed/Refractory B-Cell Malignancies
